Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the Mainsail Study.
Authors
de Morrée, EVogelzang, N
Petrylak, D
Budnik, N
Wiechno, P
Sternberg, C
Doner, K
Bellmunt, J
Burke, J
Ochoa de Olza, M
Choudhury, Ananya
Gschwend, J
Kopyltsov, E
Flechon, A
van As, N
Houede, N
Barton, D
Fandi, A
Jungnelius, U
Li, S
Li, J
de Wit, R
Affiliation
Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the NetherlandsIssue Date
2016-08-25
Metadata
Show full item recordAbstract
The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it is beneficial for patients to continue treatment upon 6 cycles.Citation
Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the Mainsail Study. 2016, JAMA OncolJournal
JAMA OncologyDOI
10.1001/jamaoncol.2016.3000PubMed ID
27560549Type
ArticleLanguage
enISSN
2374-2445ae974a485f413a2113503eed53cd6c53
10.1001/jamaoncol.2016.3000
Scopus Count
Collections
Related articles
- Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
- Authors: Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K
- Issue date: 2015 Apr
- Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
- Authors: Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP
- Issue date: 2017 Feb
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
- Authors: Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K
- Issue date: 2017 Nov
- Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
- Authors: Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F
- Issue date: 2016 Mar
- Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
- Authors: de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW
- Issue date: 2017 Apr